According to the deal, which is approved by boards of directors of both parties, Allergan will pay $22.60 per share of Soliton.

The acquisition will provide Allergan with access to Soliton’s rapid acoustic pulse (RAP) device, RESONIC. A non-invasive device indicated for improving cellulite appearance for a short course of time, RESONIC received the US Food and Drug Administration 510(k) clearance.

The RAP technology utilises non-invasive, quick, high-frequency sound waves to interrupt targeted cellular structures and connective tissue, working on the fibrous septae under the skin that cause the dimpled look of cellulite.

According to clinical trial data submitted to the FDA, a single treatment session with RESONIC showed improvement and offered patient satisfaction. About 92.9% of the participants agreed or strongly agreed that the appearance of their cellulite got better.

The latest deal will expand Allergan Aesthetics’ body contouring treatment products, including CoolSculpting Elite, the company noted.

Global Allergan Aesthetics president and AbbVie senior vice-president Carrie Strom said: “Soliton’s technology offers a new, completely non-invasive approach with clinically proven results to reduce the appearance of cellulite with no patient downtime.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The addition of this technology complements Allergan Aesthetics’ portfolio of body contouring treatments. Health care providers will now have another option to address consumers’ aesthetic concerns.”

RESONIC is also FDA 510(k)-cleared for use along with laser to remove tattoos and has shown clinical results in fibrotic scars, Allergan Aesthetics noted.

Soliton executive chairman Walter Klemp said: “Allergan Aesthetics’ brand recognition, global footprint, track record and commitment to developing best-in-class aesthetic treatments makes the company ideally suited to maximise the commercial potential of the RESONIC rapid acoustic pulse technology.”

The acquisition is subject to customary closing conditions, including antitrust clearances and Soliton’s shareholder approval.